Evofem Biosciences Inc

NASDAQ:EVFM  
0.42
-0.01 (-1.67%)
4:01:33 PM EDT: $0.42 0.00 (-0.66%)
Products

Evofem Biosciences Announces Successful Type C Meeting With FDA For STI Prevention Product Candidate

Published: 11/30/2021 13:14 GMT
Evofem Biosciences Inc (EVFM) - Evofem Biosciences Announces Successful Type C Meeting With FDA for Sti Prevention Product Candidate.
Evofem Biosciences Inc - Company Expects to Report Top-line Evoguard Data in Second Half of 2022.
Evofem Biosciences Inc - Anticipated PDUFA Date in Second Half of 2023 Due to Expedited Review Afforded by Fast Track Designations for Evoguard.